Innovative methods for treating pediatric hematologic tumors

How they work and why they save children's lives

Cancer in children and adolescents remains one of the major medical challenges. Although cases are rare, it is the second leading cause of death in children aged 1 to 14, after accidents. However, over the past 30 years the situation has dramatically improved: while around 50% of patients survived in the 1970s, today this figure exceeds 80%.

According to statistics, about 30% of all malignant tumors in children are leukemias, with acute lymphoblastic leukemia (ALL) being the most common. Lymphomas (Hodgkin and non-Hodgkin) account for 10–15% of cases and are also among the most frequent hematologic diseases.

This remarkable progress is due not only to improved chemotherapy, but also to breakthrough technologies: targeted drugs, immunotherapy, genetically modified cells, and new treatment methods. They allow for precise action, greater effectiveness and less harm to healthy tissues.

Unlike classical chemotherapy, which affects both healthy and cancer cells, targeted drugs block specific molecules or signaling pathways responsible for tumor growth. This increases treatment effectiveness and significantly reduces side effects.